- Bavarian Nordic is the only company that manufactures the monkeypox vaccine.
- After the spread, the Danish company gained up to 26% on its trades.
- This company, based in Tuborg Havn, in Copenhagen, and a workforce of 750 people, was the one who developed the drug in 2019.
The spread of monkeypox fueled the actions of Bavarian Nordic A/S, the only company that makes an approved vaccine for this viral infection.
The Danish company gained up to 26% in operations since the spread of the disease was announced
The Danish company gained as much as 26% in Copenhagen trading on Thursday after saying it had secured a contract to supply its smallpox vaccine, which is also approved against monkeypoxto an undisclosed European country.
Monkeypox or monkeypox is a virus that is endemic to some forested parts of central and western Africa, it has been found in a handful of cases in the UK, Spain and Portugal in recent days and in a person in the US
World Health Organization said Wednesday that he was monitoring a situation that “is rapidly evolving.”
The first European case was confirmed on May 7, 2022 in a person who returned from a trip to Nigeria, where monkeypox is endemic. Subsequently, more than 20 cases have been confirmed in England, Portugal and Spain and additional suspected cases are currently being investigated.
Evidence suggests that most infections have been acquired locally in these countries. In the US, a single case has been confirmed in a traveler from Canada, where no cases have yet been confirmed, but several remain under investigation.
About the company
This company, with headquarters in Tuborg Havn, in Copenhagen, and a staff of 750 people, was the one who developed the drug in 2019. The vaccine, named Jynneos, treats both general smallpox and its monkey variant. Smallpox has been eradicated since 1980 thanks precisely to the rapid spread of the vaccine.
Bavarian Nordic’s smallpox vaccine is licensed in the US as JYNNEOS ® and in Canada as IMVAMUNE ® , both locations with extended approval to cover the monkeypox indication. The vaccine is approved in Europe as IMVANEX ® for smallpox indication only, but previously provided for off-label use in response to cases of monkeypox.
Paul Chaplin, President and CEO of Bavarian Nordic, said: “While all the circumstances surrounding the current cases of monkeypox in Europe have not yet been elucidated. The speed at which they have evolved, combined with the potential for infections beyond the initial case to go undetected, calls for a swift and coordinated approach by health authorities, and we are pleased to assist in this emergency situation.”
“Infection control has been a high priority for societies since COVID-19, and this situation is an unfortunate reminder that we cannot let our guard down, but must continue to build and strengthen our infectious disease preparedness to keep the world safe. open,” he concluded.
Related Notes:
Fire takis lover? Nutritionist explains the danger of its consumption
How much do public hospitals in Mexico spend on the RENT of their equipment?
New cases of virus more deadly than covid-19 found in Qatar